Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

Executive Summary

Things couldn't have gone any worse for Bristol-Myers Squibb's Opdivo in the CheckMate 026 lung cancer data presented at ESMO. Without even a trend towards efficacy in patients with high levels of PD-L1 expression, imminent erosion of market share by Merck's Keytruda seems inevitable.


Related Content

NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations
4Q Pharma Results Preview, Part 2: Pfizer, Lilly, Roche, AstraZeneca, Merck, Amgen, Novo
Under Fire, Bristol Plans To Pick Up The IO Pieces
Bristol, AstraZeneca Changes To IO Strategy Could Ultimately Be Regulatory Gain
4Q Pharma Results Preview: J&J, Novartis, Bristol, Celgene, Biogen
Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing
AstraZeneca Updates MYSTIC Plan In Bid To Challenge Merck In NSCLC
ESMO Preview: Opdivo Under Pressure
Does CheckMate 026 Take Bristol Out Of The End Game?
What's Next For Bristol's Opdivo/Yervoy Combination


Related Companies